title: Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial.
abstract: Vinorelbine intravenously (i.v.) demonstrated its efficacy and tolerability in advanced non-small cell lung cancer (NSCLC) patients, including elderly subjects. Since vinorelbine is now available as an oral formulation this phase II open study was designed to evaluate its activity and tolerability in advanced, elderly NSCLC patients. A total of 56 chemonaive patients were recruited from April 2001 through to March 2002. The dosage schedule, already tested in younger NSCLC patients, was 60 mg/m(2)once a week for three weeks (first cycle), followed by 80 mg/m(2) once a week until disease progression or development of unacceptable toxicity. A limited sampling scheme was used for performing pharmacokinetic analysis on 52 of 56 patients enrolled in the study. Treatment was well tolerated with grade 3/4 neutropenia in 11/17 patients (20/30%) and febrile neutropenia in 1 (2%). Six partial responses (11%) and 25 stable disease responses were recorded, with a disease control rate of 55%. Median overall survival was 8.2 months (95% Confidence Interval (CI) [6.2-11.3]). The clinical benefit response rate was 31% on 32 evaluable patients. Pharmacokinetic profiles appeared quite similar to the historical profiles recorded following i.v. administration. Oral vinorelbine appears to be a reasonable alternative to i.v. vinorelbine, both in terms of activity and tolerability, in advanced, elderly NSCLC patients.
authors.affiliation: Unità Operativa di Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Via Circumvallazione 68, Avellino 83100, Italy. cgridelli@libero.it
authors.forename: C
authors.initials: C
authors.lastname: Gridelli
authors.forename: C
authors.initials: C
authors.lastname: Manegold
authors.forename: P
authors.initials: P
authors.lastname: Mali
authors.forename: M
authors.initials: M
authors.lastname: Reck
authors.forename: L
authors.initials: L
authors.lastname: Portalone
authors.forename: O
authors.initials: O
authors.lastname: Castelnau
authors.forename: R
authors.initials: R
authors.lastname: Stahel
authors.forename: D
authors.initials: D
authors.lastname: Betticher
authors.forename: M
authors.initials: M
authors.lastname: Pless
authors.forename: J Terrassa
authors.initials: JT
authors.lastname: Pons
authors.forename: D
authors.initials: D
authors.lastname: Aubert
authors.forename: J-P
authors.initials: JP
authors.lastname: Burillon
authors.forename: Y
authors.initials: Y
authors.lastname: Parlier
authors.forename: F
authors.initials: F
authors.lastname: De Marinis
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine